Purchase Order 75N93022P01157

This firm-fixed-price purchase order was awarded by the National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, to Genscript USA Inc., a for-profit biotechnology company. The $118,272.00 contract is for the provision of customized antibody expressions and plasmid preparations to support biomedical research and public health initiatives. The award has a completion date of November 1, 2020 and does not include a set-aside designation. Genscript...

This $227,348.40 firm fixed-price purchase order was awarded by the Centers for Disease Control and Prevention (CDC) to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract is for the production of focused antibodies and DNA to support the CDC's Influenza Division in the development and characterization of Candidate Vaccine Viruses (CVVs) for influenza pandemic preparedness. This requirement is driven by the constant genetic changes in circulating and novel...

Genscript USA Inc. was awarded a $54,900 firm-fixed price purchase order by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases to provide customized antibody and plasmid preparation services. The award is associated with a pre-solicitation notice indicating the NIAID's intent to negotiate on a sole-source basis with Genscript for 100 customized antibodies and 200 plasmid preparations to support identification of...

This purchase order contract was awarded by the National Institutes of Health's National Institute of Child Health and Human Development to Becton, Dickinson and Company BD Biosciences, Systems and Reagents Division for the delivery of antibodies against HLA-DR labeled with APC-Cy7. Valued at approximately $6,901, the firm fixed price contract calls for the provision of ANTIBODIES: ANTI-HLA-DR APC-CY7 L243 (G46-6) RUO/GMP CATALOG# 335796 to the prime contractor's facility in Bethesda,...

This firm fixed-price purchase order for approximately $54,700 was awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Sino Biological US Inc. to support antiviral drug development efforts. Under the contract, Sino Biological will generate hybridoma cell lines and monoclonal antibodies targeting four viral proteins of priority pathogens identified by the Antimicrobial Resistance Coordination and Strategy Unit. The work includes providing...

This firm fixed price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Geneimmune Biotechnology Corp., a biotechnology company based in Rockville, Maryland. The $31,435.00 contract is for the production of 20 liters of monoclonal antibodies at $1,500 per liter. This award supports NIAID's infectious disease research efforts, leveraging Geneimmune's expertise in areas such as gene...

This firm fixed price purchase order was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Life Technologies Corporation for $35,692.80. The contract calls for Life Technologies to deliver 80 units of heat inactivated fetal bovine serum with lot number 2661794P to the NIH Clinical Center in Bethesda, Maryland. The serum will support ongoing cell culture work and clinical research being performed by the Laboratory of Immunoregulation's HIV...

This firm fixed price purchase order was awarded by the National Institutes of Health National Cancer Institute to Genscript USA Inc. for $30,280. The contract is for the acquisition of recombinant antibody against mouse ErbB2 (HER2) domain IV via custom protein production services. Specifically, Genscript will immunize rabbits with the antigen protein, collect B cell clones to screen for binding to mouse HER2, collect supernatants from 20 antibody clones, and produce and purify the...

The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $12,622.50 firm fixed price purchase order to Stemcell Technologies Inc. for cell culture medium under catalog number 2201103. Stemcell Technologies, whose parent company is also Stemcell Technologies, will deliver the requested products from its location in Kent, Washington by January 31, 2024 to support the NIH/NIAID's research efforts. No subcontractors or...

This firm fixed-price purchase order, valued at $16,215, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract is for the provision of monoclonal antibodies and plasmids services to support NIAID's biomedical research and public health initiatives. Genscript, a for-profit organization, has received numerous prime...